Large-cap Health Care company Elevance Health has moved 0.3% so far today on a volume of 119,603, compared to its average of 1,153,979. In contrast, the S&P 500 index moved -0.0%.
Elevance Health trades -22.94% away from its average analyst target price of $569.78 per share. The 18 analysts following the stock have set target prices ranging from $493.0 to $629.0, and on average have given Elevance Health a rating of buy.
If you are considering an investment in ELV, you'll want to know the following:
-
Elevance Health's current price is 54.3% above its Graham number of $284.59, which implies that at its current valuation it does not offer a margin of safety
-
Elevance Health has moved -8.0% over the last year, and the S&P 500 logged a change of 14.0%
-
Based on its trailing earnings per share of 26.88, Elevance Health has a trailing 12 month Price to Earnings (P/E) ratio of 16.3 while the S&P 500 average is 15.97
-
ELV has a forward P/E ratio of 11.9 based on its forward 12 month price to earnings (EPS) of $37.01 per share
-
The company has a price to earnings growth (PEG) ratio of 1.04 — a number near or below 1 signifying that Elevance Health is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 2.71 compared to its sector average of 4.16
-
Elevance Health, Inc. operates as a health benefits company.
-
Based in Indianapolis, the company has 102,300 full time employees and a market cap of $103.47 Billion. Elevance Health currently returns an annual dividend yield of 1.3%.